Since March of 2017, Waneta has been the managing partner of Tramway Venture Partners, a seed-stage venture fund which to date has invested in Armonica Technologies (long read DNA sequencing), BennuBio (high throughput flow cytometry), and WaveFront Dynamics (ophthalmic medical device). She is founder and chief executive officer of Southwest Medical Ventures, which started Tullis portfolio company Exagen, Indigo Medical (acquired by Johnson & Johnson), PhDx Systems, nanoMR, Inc (acquired by DNAe of the U.K.) and Agilvax.

In addition to serving on the boards of Tramway’s and Southwest Medical’s portfolio companies, Waneta was previously a member of the corporation at the Charles Stark Draper Laboratories in Boston; served for ten years on the Board of Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, Montana, New Mexico and Montana – the nation’s fourth largest health insurer); and was a Director of NASDAQ-listed MGI Pharma through its sale to Eisai Pharmaceuticals.

Waneta holds a doctorate in biology with a concentration in physiology and a Master of Business Administration from the University of New Mexico, where she has been inducted into the R.O. Anderson School of Management’s Hall of Fame and served as Alumni Association president.